Showing results (501-510 of 645) with videos related to
Sort By:
Pageof 65
Journal of Alzheimer'S Disease Reports|October 3, 2022
Temporal Cortical Thickness and Cognitive Associations among Typical and Atypical Phenotypes of Alzheimer's DiseaseAlissa M Butts, Mary M Machulda, Peter Martin, et al.Leukemia|August 21, 2021
Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patientsSelcen Öztürk, Yashna Paul, Saira Afzal, et al.BMC Medical Genomics|January 22, 2011
EMT is the dominant program in human colon cancerAndre Loboda, Michael V Nebozhyn, James W Watters, et al.Circulation Research|March 5, 2024
Characterization of Vascular Niche in Systemic Sclerosis by Spatial ProteomicsAleix Rius Rigau, Yi-Nan Li, Alexandru-Emil Matei, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 12, 2019
The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's diseaseJennifer L Whitwell, Peter Martin, Jonathan Graff-Radford, et al.Cell Death Discovery|June 11, 2024
Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs)Laura Schmitt, Julia Hoppe, Pablo Cea-Medina, et al.BMJ (Clinical Research Ed.)|December 18, 2014
SearCh for humourIstic and Extravagant acroNyms and Thoroughly Inappropriate names For Important Clinical trials (SCIENTIFIC): qualitative and quantitative systematic studyAnton Pottegård, Maija Bruun Haastrup, Tore Bjerregaard Stage, et al.BMC Cancer|May 8, 2021
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United KingdomJason Lester, Carles Escriu, Sarah Khan, et al.Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell LymphomaStephen E Spurgeon, Brian G Till, Peter Martin, et al.Blood|September 6, 2018
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphomaJia Ruan, Peter Martin, Paul Christos, et al.Pageof 65